ライフサイエンスコーパス: dependent kinase

1 Fin1 and Dam1, and phosphorylation by cyclin-dependent kinase.

2 on mediated by signaling pathways and cyclin-dependent kinases.

3 peptides that bind to a subset of the cyclin-dependent kinases.

4 hich is controlled by the activity of cyclin-dependent kinases.

5 sphatidylinositol 3-kinase (PI3K) and cyclin-dependent kinases.

6 of ATR ablation is not due to altered cyclin-dependent kinase 1 (CDK1) activity, DNA damage responses

7 DF2 protein stability is dependent on cyclin-dependent kinase 1 (CDK1) activity.

8 is hyperpolarization was dependent on cyclin-dependent kinase 1 (CDK1) activity.

9 entry initiated by the activities of Cyclin-dependent kinase 1 (CDK1) and Polo-like kinase 1 (PLK1),

10 The cyclin-dependent kinase 1 (Cdk1) drives cell division.

11 hosphorylated in vitro and in vivo by cyclin-dependent kinase 1 (CDK1) during antimitotic drug-induce

12 We found that cyclin-dependent kinase 1 (CDK1) phosphorylated a threonine res

13 (Aurora A)/Polo-like kinase 1 (PLK1)/cyclin-dependent kinase 1 (CDK1) signaling pathway was the main

14 STING led to premature activation of cyclin-dependent kinase 1 (CDK1), early onset to S-phase and mi

15 totic activation of Gwl requires both cyclin-dependent kinase 1 (CDK1)-dependent phosphorylation and

16 arge part by a switch from mTORC1- to cyclin-dependent kinase 1 (CDK1)-mediated regulation.

17 activation of Aurora A, Aurora B, and cyclin-dependent kinase 1 (CDK1).

18 B is phosphorylated at Ser1456 by the cyclin-dependent kinase 1 (CDK1).

19 uring mitosis through the activity of cyclin-dependent kinase 1 (CDK1)/cyclin B rather than through c

20 we identified a metabolic function of cyclin-dependent kinase 1 (CDK1)/cyclin B1-the activation of mi

21 l inositol-3-kinase (PI3K), phosphoinositide-dependent kinase 1 (PDK1 or PDPK1), and protein kinase B

22 at inhibition of the G(2)/M regulator cyclin-dependent kinase 1 decreases BMP (bone morphogenetic pro

23 lso results in constitutive phosphoinositide-dependent kinase 1 gain of function.

24 ion with decreased phosphorylation of cyclin-dependent kinase 1 staining by immunohistochemistry afte

25 nase kinase, ribosomal S6 kinase, and cyclin-dependent kinase 1/2 in combination with Bcl-XL inhibiti

26 ATR (ATM and Rad3-related) and by the cyclin-dependent kinases 1 and 2.

27 1) exists as 2 isoforms that regulate cyclin-dependent kinase-1 activation and chromosome condensatio

28 were sufficient to activate phosphoinositide-dependent kinase-1 to phosphorylate AKT on Thr-308 but i

29 CPH1 isoforms are phosphorylated in a cyclin-dependent kinase-1-dependent manner in mitosis and ident

30 3'-Phosphoinositide-dependent-Kinase-1 (PDK1) is a master regulator whereby

31 LIP and ChIP-seq, we found that human cyclin-dependent kinase 11 (CDK11) associates with RNA and chro

32 Cyclin-dependent kinase 12 (CDK12) modulates transcription elon

33 Genetic depletion of cyclin-dependent kinase 12 (CDK12) or selective inhibition of a

34 Cyclin-dependent kinase 12 (CDK12) phosphorylates the carboxyl-

35 orylation (activation) of calcium/calmodulin-dependent kinase 2 (CaMKII) and also that inhibition of

36 nE1) is the regulatory subunit of the cyclin-dependent kinase 2 (Cdk2) and controls cell cycle re-ent

37 s by regulating the expression of the cyclin-dependent kinase 2 (CDK2) and cyclin D1 proteins.

38 -181c significantly inhibited phospho-cyclin-dependent kinase 2 (CDK2) and cyclin-A expression, arres

39 thway reversed quiescence by inducing cyclin-dependent kinase 2 (CDK2) and reducing p21(CIP1) and NEU

40 Cyclin-dependent kinase 2 (CDK2) drives the progression of cell

41 Cyclin-dependent kinase 2 (CDK2) is a potential therapeutic tar

42 Cyclin-dependent kinase 2 (CDK2) is known to localize to so-cal

43 Whereas cyclin-dependent kinase 2 (Cdk2) is not necessary for mouse via

44 y, we and others report that cyclin E/cyclin-dependent kinase 2 (CDK2) phosphorylates enhancer of zes

45 e show that the cell cycle regulator, cyclin-dependent kinase 2 (CDK2), couples primary beta-cell dys

46 ed with Cell Division Cycle 6 (CDC6), Cyclin-dependent kinase 2 (CDK2), Cyclins D1 and D3, indicating

47 Expression of the cyclin-dependent kinase 2 (CDK2), itself a downstream target of

48 onjunction with its catalytic partner cyclin-dependent kinase 2 (CDK2), regulates cell cycle progress

49 ted cell division cycle 7 (CDC7)- and cyclin-dependent kinase 2 (CDK2)-dependent reactivation of the

50 death of cardiomyocytes by activating cyclin-dependent kinase 2 (CDK2).

51 of TP63 expression and phosphorylated cyclin-dependent kinase 2 levels.

52 he approach is illustrated by mapping cyclin-dependent kinase 2, which successfully identifies orthos

53 orylation is driven by the actions of cyclin-dependent kinases 2 and 4/6 at G1/S cell-cycle checkpoin

54 lammatory signaling pathway driven by cyclin-dependent kinase 4 (CDK4) and CDK6 and the methyltransfe

55 regulated in malignant cells, such as cyclin-dependent kinase 4 (CDK4) and CDK6, have attracted consi

56 Cyclin-dependent kinase 4 (CDK4) is well-known for its role in

57 Cyclin D-Cyclin-Dependent Kinase 4 (CDK4)-dependent phosphorylation of p

58 revealed a specific interaction with cyclin-dependent kinase 4 (CDK4).

59 on that results in hyperactivation of cyclin-dependent kinase 4 and 6 (CDK4/6), rather than by the hu

60 tivated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo.

61 ny older women will be treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and an aromatase

62 We aimed to develop a radiolabeled cyclin-dependent kinase 4/6 (CDK4/6) inhibitor for breast cance

63 Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are an establis

64 highly sensitive to the inhibition of cyclin-dependent kinase 4/6 (CDK4/6).

65 trant is combined with palbociclib (a cyclin-dependent kinase 4/6 inhibitor), adding periodic cycles

66 ized with approved anti-estrogens and cyclin-dependent kinase 4/6 inhibitors (CDK4/6(i)).

67 Cyclin-dependent kinase 4/6 inhibitors (CDKIs) are indicated wi

68 ation of a MEK inhibitor with PI3K or cyclin-dependent kinase 4/6 inhibitors.

69 thality between decreased activity of cyclin-dependent kinases 4 and 6 (CDK4/6) and VHL inactivation

70 Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamental drive

71 Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of

72 We identify cyclin-dependent kinases 4 and 6 (CDK4/6) as essential regulato

73 Deregulation of cyclin-dependent kinases 4 and 6 (CDK4/6) is highly prevalent i

74 Cyclin-dependent kinases 4 and 6 (CDK4/6) phosphorylate and inh

75 HER2-targeted therapy, inhibitors of cyclin-dependent kinases 4 and 6, angiogenesis inhibitors, poly

76 atidylinositol-3 kinase (PI3K) and/or cyclin-dependent kinases 4/6 (CDK4/6).

77 dies suggest that deregulation of p25/Cyclin-dependent kinase 5 (Cdk5) activity leads to the hyperpho

78 Furthermore, Cadm4, cyclin-dependent kinase 5 (Cdk5) and p39 mRNAs were significant

79 Here we investigate the inhibition of cyclin-dependent kinase 5 (Cdk5) as a promising combination str

80 Cyclin-dependent kinase 5 (Cdk5) has been involved in processes

81 and upregulates Ca(V)3.2 channels and cyclin-dependent kinase 5 (Cdk5) in dorsal root ganglia (DRG) a

82 ntly identified an essential role for cyclin-dependent kinase 5 (Cdk5) in T-cell activation and effec

83 Cyclin-dependent kinase 5 (CDK5) is known to underlie both fear

84 cell signals for CAP1, we found that cyclin-dependent kinase 5 (CDK5) phosphorylates both Ser307 and

85 Here, we show that the cyclin-dependent kinase 5 (CDK5) regulates the mammalian circad

86 Here, we show that cyclin-dependent kinase 5 (Cdk5), a protein kinase that regulat

87 The cyclin-dependent kinase 5 (CDK5), originally described as a neu

88 known to induce aberrant activity of cyclin-dependent kinase 5 (Cdk5), which is associated with neur

89 24) and Ser(429) in the C terminus by cyclin-dependent kinase 5 (Cdk5).

90 phamine treatment was shown to reduce cyclin-dependent kinase 5 in patient cells, suggesting a conver

91 glycogen synthetase kinase 3beta and cyclin-dependent kinase 5 is required to prevent P301L-induced

92 glycogen synthetase kinase 3beta and cyclin-dependent kinase 5 prevents tau mislocalization to dendr

93 7j is highly effective in preventing cyclin-dependent kinase 5-mediated phosphorylation of PPARgamma

94 to tau phosphorylation by activating cyclin-dependent kinase 5.

95 ulation of its proven targets, namely cyclin-dependent kinase 6 and Mcl1.

96 novel treatment strategy that targets cyclin-dependent kinase 7 (CDK7) in HER2 inhibitor-resistant (H

97 ings demonstrate that pharmacological cyclin-dependent kinase 7 (CDK7) inhibitors can evoke anticance

98 Cyclin-dependent kinase 7 (CDK7) is a central regulator of the

99 Cyclin-dependent kinase 7 (CDK7) is the catalytic subunit of th

100 ocks glucose consumption by targeting cyclin-dependent kinase 7 (CDK7) similar to other CDK7 inhibito

101 Cyclin-dependent kinase 7 (CDK7), Cyclin H, and the RING-finger

102 inery and especially to inhibition of cyclin-dependent kinase 7 (CDK7), which is essential for the tr

103 lar, to THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7).

104 odule that includes the MED13, MED12, cyclin-dependent kinase 8 (CDK8), and cyclin C (CCNC) subunits.

105 The activity of its catalytic core, cyclin-dependent kinase 8 (CDK8), is controlled by Cyclin C and

106 ic process: a new replication factor, cyclin-dependent kinase 8/19-cyclinC (Cdk8/19-cyclin C), binds

107 We identify cyclin dependent kinase 9 (CDK9) as a novel binding partner of

108 We found that SIRT2 deacetylates cyclin-dependent kinase 9 (CDK9) in a type I IFN-dependent mann

109 Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker a

110 rylation of elongation factor Spt5 by cyclin-dependent kinase 9 (Cdk9) occur during transcription by

111 Mechanistically, BRD4 is required for cyclin-dependent kinase 9 (CDK9) recruitment and phospho-Ser 2

112 K9ac) and 56 (H3K56ac), activation of cyclin-dependent kinase 9 (CDK9)-that phosphorylates NELF and t

113 ontaining 4 (BRD4) with NF-kappaB and cyclin-dependent kinase 9 (CDK9).

114 Inhibition of both cyclin-dependent kinase 9 activity and viral DNA replication re

115 as a substrate for the P-TEFb kinase cyclin-dependent kinase 9, which triggers release of polymerase

116 ed at an N-terminal serine cluster by cyclin-dependent kinase-9 (CDK9), which is recruited into GC-in

117 tion of the core cell cycle regulator CYCLIN-DEPENDENT KINASE A;1 (CDKA;1) and that this repression i

118 al two-step mechanism in which 1) the cyclin-dependent kinase activating kinase Cak1 phosphorylaytes

119 uggest that stimulation of autophagy by cAMP-dependent kinase activation might conceivably rescue the

120 aryote Saccharomyces cerevisiae, Cln3-cyclin-dependent kinase activity enables Start, the irreversibl

121 cursor to NAD(+) Cell lysates possess an ATP-dependent kinase activity that efficiently converts NRH

122 his study was to evaluate the role of an AMP-dependent kinase (AMPK) activator, 5-aminoimidazole-4-ca

123 yme, we obtain the first structure of an ADP-dependent kinase (AncMsPFK) with F6P at its active site.

124 karyotes and, despite lacking obvious cyclin-dependent kinase and cyclin homologs, has an ordered euk

125 entified kenpaullone, an inhibitor of cyclin-dependent kinases and glycogen synthase kinase 3, as a m

126 Cyclins, cyclin-dependent kinases and other components of the core cell

127 regulators of the G(1) phase, such as cyclin-dependent kinases and pRb (retinoblastoma protein), are

128 eted by the kinases protein kinase C, cyclin-dependent kinase, and mitogen-activated protein kinase s

129 upregulation of p21, an inhibitor of cyclin-dependent kinases, and blocked G1 arrest after TBI there

130 the epidermal growth factor receptor, cyclin-dependent kinases, and heat shock protein 90.

131 Cyclin-dependent kinases are therapeutic targets frequently der

132 how they led to the identification of cyclin-dependent kinases as core to these cell cycle controls.

133 se synchronisation of the activity of cyclin dependent kinases at distinct stages of the cell cycle,

134 ted: inhibition of the autoactivated calcium-dependent kinase (calmodulin kinase II [CaMKII]) via the

135 of phagophore formation requires the calcium-dependent kinase CaMKKbeta and AMPK, which increase the

136 Activation of MutSgamma requires the Dbf4-dependent kinase Cdc7 (DDK), which directly phosphorylat

137 Here, we demonstrate that the cyclin-dependent kinase CDK-1 primes the recruitment of PLK-2 t

138 The development and approval of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for hormone re

139 of the retinoblastoma (RB) protein by cyclin-dependent kinase (CDK) 4/6 and increased G1-S progressio

140 represents the downstream target for cyclin-dependent kinase (CDK) 4/6 inhibitors that are in clinic

141 alog 24), which selectively inhibited cyclin-dependent kinase (CDK) 5 over CDK2 in cancer cell lines.

142 Cyclin-dependent kinase (CDK) 7 has a unique functional reperto

143 g kinase (CAK), a complex composed of cyclin-dependent kinase (CDK) 7, cyclin H, and MAT1, is a criti

144 Although cyclin-dependent kinase (CDK) 9 has an established pathogenic r

145 s ordered by thresholds of increasing cyclin-dependent kinase (Cdk) activity.

146 urther required to promote loading of cyclin-dependent kinase (CDK) and proliferating cell nuclear an

147 demonstrated for other substrates, as cyclin-dependent kinase (CDK) binding-defective mutants are cap

148 Cip1) /p27(Kip1) ) inhibit cyclin and cyclin-dependent kinase (CDK) complex that promotes fibrosis an

149 p27) tumor suppressor inhibits cyclin/cyclin-dependent kinase (CDK) complexes and halts cell cycle pr

150 Cyclin D-CDK4/6 are the first cyclin-dependent kinase (CDK) complexes to be activated by mito

151 ilizes and increases the level of the cyclin-dependent kinase (CDK) inhibitor p27, which inhibits cel

152 psis (Arabidopsis thaliana) encodes a cyclin-dependent kinase (CDK) inhibitor that plays a central ro

153 er cell lines(3-5), we identify CR8-a cyclin-dependent kinase (CDK) inhibitor(6)-as a compound that a

154 OR inhibition blunts the induction of cyclin-dependent kinase (CDK) inhibitors (CDKIs), including p16

155 activity, increased expression of the cyclin-dependent kinase (CDK) inhibitors p16INK4A (CDKN2A) and

156 in chordoma, and that transcriptional cyclin-dependent kinase (CDK) inhibitors targeting CDK7/12/13 a

157 Since cyclin-dependent kinase (CDK) inhibitors, CDKN2A and CDKN2B, an

158 arrested because of the expression of cyclin-dependent kinase (CDK) inhibitors.

159 on and development independent of its cyclin-dependent kinase (CDK) inhibitory action.

160 n host cells because the HCMV-encoded cyclin-dependent kinase (CDK) ortholog pUL97 extensively phosph

161 t of anaphase, is mediated by mitotic cyclin-dependent kinase (CDK) phosphorylation of the GTPase's d

162 Here, we adapt a cyclin-dependent kinase (CDK) sensor to uncouple these key even

163 multisite phosphorylation networks of cyclin-dependent kinase (CDK) targets have opened a new level o

164 e master regulator of the cell cycle, cyclin-dependent kinase (CDK), temporally coordinates an array

165 ivation loop is phosphorylated by the cyclin-dependent kinase (CDK)-activating kinase (Cak1), and Y20

166 s that is controlled by the conserved cyclin-dependent kinase (CDK)-cyclin protein complex(1).

167 The cyclin-dependent kinase (CDK)-RB-E2F axis forms the core transc

168 counterbalance its phosphorylation by cyclin-dependent kinase (Cdk).

169 ndle pathway and under the control of cyclin-dependent kinase (CDK).

170 isordered protein (IDP) that inhibits cyclin-dependent kinase (Cdk)/cyclin complexes (e.g., Cdk2/cycl

171 Cyclin-dependent kinase (CDK)/cyclin complexes drive most proce

172 e, we described that the complex Clb2-cyclin-dependent kinase (Cdk)1, one of the master regulators of

173 Cyclin-dependent kinase (CDK)6 is a member of the CDK family of

174 Brd4 and cyclin-dependent kinases (CDK) had critical regulatory roles in

175 ere highly sensitive to inhibitors of cyclin-dependent kinases (CDK), especially THZ1, a covalent inh

176 es a decisive shift in the balance of cyclin-dependent kinase Cdk1 and PP2A:B55 activity.

177 otein kinase Wee1, which inhibits the cyclin-dependent kinase Cdk1 in yeast through human cells.

178 bistability in the activation of the cyclin-dependent kinase Cdk1.

179 in yeast Hsp70 (Ssa1) is promoted by cyclin-dependent kinase (Cdk1) during normal growth.

180 Cyclin B-dependent kinase (CDK1-CCNB1) promotes entry into mitosi

181 Phosphorylation of Sae2 by cyclin-dependent kinase (CDK1/Cdc28) activates the Mre11 endonu

182 ed using a bioinformatics strategy as cyclin-dependent kinases CDK2 and CDK9 inhibitors, which play c

183 st when bound in ternary complex with cyclin-dependent kinase (Cdk2) and cyclins (e.g., Cdk2/Cyclin A

184 We demonstrate that cyclin-dependent kinase (CDK2) can bind to the promoters of a n

185 , we show that CNTD1 interacts with a cyclin-dependent kinase, CDK2, which also accumulates in crosso

186 d in most human cancers, and specific cyclin-dependent kinase Cdk4/6 inhibitors are approved or in cl

187 te the RB pathway using inhibitors of cyclin-dependent kinases CDK4 and CDK6 are effective in some ca

188 th transcriptomic analysis identifies cyclin-dependent kinases CDK4 and CDK6 as regulators of metasta

189 The cyclin-dependent kinases Cdk4 and Cdk6 form complexes with D-ty

190 Although the cyclin-dependent kinases CDK4 and CDK6 play fundamental roles i

191 ibitors of mTOR and inhibitors of the cyclin-dependent kinases CDK4 and CDK6 substantially improve pr

192 Cyclin D dependent kinases (CDK4 and CDK6) regulate entry into S

193 Cyclin C-cyclin-dependent kinase (Cdk8) is a component of the RNA polyme

194 ctylum tricornutum, by binding to two cyclin-dependent kinases, CDKA1 and CDKA2.

195 actor TRF2 within the promoter of the cyclin-dependent kinase CDKNIA (p21/CIP1/WAF1).

196 The cyclin-dependent kinases (CDKs) 12 and 13 phosphorylate the C-t

197 irmed high selectivity of 4.35 toward cyclin-dependent kinases (CDKs) 2, 5, and 9, and the cocrystal

198 is strictly controlled by a number of cyclin-dependent kinases (CDKs) and CDK inhibitors (CKIs), the

199 Furthermore, proper levels of cyclin dependent kinases (CDKs) and cyclins, including D-type c

200 c) kinase subunit (CKS) proteins bind cyclin-dependent kinases (CDKs) and play important roles in cel

201 controlled by the conserved family of cyclin-dependent kinases (CDKs) and their partner cyclins.

202 Cyclin-dependent kinases (CDKs) are frequently deregulated in c

203 Increasing evidence suggests that cyclin-dependent kinases (Cdks) are inappropriately activated i

204 Cyclin-dependent kinases (Cdks) are principal drivers of cell d

205 The cyclin-dependent kinases (CDKs) are the major cell-cycle regula

206 r of PAH pathobiology, and identified cyclin-dependent kinases (CDKs) as overactivated kinases in spe

207 gered by variation in the activity of cyclin-dependent kinases (CDKs) bound to cyclins.

208 , cyclin-specific docking motifs help cyclin-dependent kinases (CDKs) phosphorylate different substra

209 Furthermore, we show that cyclin-dependent kinases (CDKs) phosphorylate PAH1 at serine 16

210 Cyclin-dependent kinases (CDKs) regulate cell cycle progression

211 signaling, restricts the activity of cyclin-dependent kinases (CDKs) that promote cell division.

212 cycle progression in conjunction with cyclin-dependent kinases (CDKs).

213 tion and acts primarily by inhibiting cyclin-dependent kinases (CDKs).

214 Mcm2 promotes the stable recruitment of Dbf4-dependent kinase (DDK) to Mcm2-7 double hexamers, which

215 d major cell-cycle kinase, Cdc7-Dbf4 or Dbf4-dependent kinase (DDK).

216 otein-E2F binding specificity and how cyclin-dependent kinases differentially regulate pocket protein

217 inal domain that is phosphorylated by cyclin-dependent kinases during the transition from initiation

218 ated kinase-ribosomal S6 PK-phosphoinositide-dependent kinase (ERK-RSK-PDK) complex is an excellent e

219 changes in substrate specificity during ADP-dependent kinase evolution along with the structural det

220 ypanosoma brucei CRK9 is an essential cyclin-dependent kinase for the parasite-specific mode of pre-m

221 n assay, we determine that execution of Dbf4-dependent kinase function, including Cdc45 loading, resu

222 he Arabidopsis (Arabidopsis thaliana) cyclin-dependent kinase G1 (CDKG1) is necessary for recombinati

223 oted the activation of the Ca(2+)/calmodulin-dependent kinase II (CaMKII) and the phosphorylation of

224 we have targeted the host calcium/calmodulin-dependent kinase II (CaMKII) for inhibition.

225 Calcium-calmodulin-dependent kinase II (CaMKII) has an important role in de

226 Calmodulin-dependent kinase II (CaMKII) has long been known to play

227 nduced calcium signaling, calcium/calmodulin-dependent kinase II (CaMKII) phosphorylates OGT, which i

228 Calcium/calmodulin-dependent kinase II (CaMKII) plays a key role in the pla

229 ch as fibroblast growth factors (FGF) or CaM-dependent kinase II (CaMKII)) that can also modify chann

230 xpressing myocytes caused calcium/calmodulin-dependent kinase II activation and altered myocyte bioen

231 naptic cell surface, in a calcium/calmodulin-dependent kinase II and protein kinase G-dependent manne

232 osphorylation site for the Ca(2+)/calmodulin-dependent kinase II at serine 315.

233 phosphorylated at Ser133, calcium-calmodulin-dependent kinase II phosphorylated at Thr286, and brain-

234 CaMKII (Ca(2+)/calmodulin-dependent kinase II) enhances I(Na,L) in response to inc

235 Unlike the CaMKII (Ca(2+)/calmodulin-dependent kinase II)-dependent JNK2 action in SR Ca(2+)

236 cre mouse line driven by calcium/calmodulin-dependent kinase IIalpha promoter also eliminated cocain

237 Sex-dependent associations involve cyclin-dependent kinases in bladder cancer, the MAPK signaling

238 gnized convergence of Shh agonism and cyclin-dependent kinase inhibition as potential therapeutic tar

239 in cellular ATP synthesis, activation of AMP-dependent kinase, inhibition of mTOR signaling, and indu

240 These include the cyclin-dependent kinase inhibitor (CDKI) p18INK4c, the master t

241 el of resistance to a pharmacological cyclin-dependent kinase inhibitor (CDKi), we show that this ass

242 how that polymersomes can deliver the cyclin-dependent kinase inhibitor (R)-roscovitine into human ne

243 the absence of Jdp2, a complex of the cyclin-dependent kinase inhibitor 1 (p21(Cip1)) and Nrf2 bound

244 and induces expression of p(21CIP1) (cyclin-dependent kinase inhibitor 1), and p(27KIP1) (cyclin-dep

245 CA2 DNA repair associated (BRCA2) and cyclin-dependent kinase inhibitor 1A (CDKN1A) interacting prote

246 Expression levels of the Cyclin-dependent kinase inhibitor 1a (CDKN1A), Growth/different

247 hort-term NEUROG3 expression required cyclin-dependent kinase inhibitor 1A (CDKN1A)/p21(CIP1) express

248 nd p38 MAPK-dependent upregulation of cyclin-dependent kinase inhibitor 1A (Cdkn1a, encoding for p21(

249 genes, and we identified the mRNA of cyclin-dependent kinase inhibitor 1A (Cdkn1a, p21) as a direct

250 m was identified as downregulation of cyclin-dependent kinase inhibitor 1B (p27(Kip1)) via upregulati

251 t kinase inhibitor 1), and p(27KIP1) (cyclin-dependent kinase inhibitor 1B) expression, key cell cycl

252 fying the well-known tumor suppressor cyclin dependent kinase inhibitor 2A (Cdkn2a), whose alternativ

253 enes RB1 (retinoblastoma) and CDKN2a (cyclin-dependent kinase inhibitor 2a) are critical cell-cycle r

254 Increased expression of CDKN2A (cyclin-dependent kinase inhibitor 2A)-a downstream target of E2

255 d 3-fold hypomethylation of the human cyclin-dependent kinase inhibitor 2B (CDKN2B or p15) gene promo

256 with reduced levels of the p21(Cip1) cyclin-dependent kinase inhibitor and tumor suppressor protein.

257 Both SCF complexes targeted the cyclin-dependent kinase inhibitor Cdkn1b for polyubiquitination

258 nd Enhancer of Split 1 (HES1) and the cyclin-dependent kinase inhibitor CDKN1C/p57 as novel targets o

259 Here, we show that the cyclin-dependent kinase inhibitor Dacapo (Dap; ortholog of p57(

260 e found that the expression of p21, a cyclin-dependent kinase inhibitor involved in cell cycle regula

261 orted to control the stability of the CYCLIN-DEPENDENT KINASE inhibitor KIP-RELATED PROTEIN (KRP), wh

262 ccompanied by increased expression of cyclin-dependent kinase inhibitor p21 and decreased expression

263 The cyclin-dependent kinase inhibitor p21 is an important player in

264 ease in the tumor protein p53 and the cyclin-dependent kinase inhibitor p21WAF1/CIP1, which are findi

265 liferation and elevated expression of cyclin-dependent kinase inhibitor P27 (P27KIP1) in a GEF-H1/RHO

266 ributed to elevated expression of the cyclin-dependent kinase inhibitor p27, a Siah2 substrate.

267 The cyclin-dependent kinase inhibitor p57(kip2) is encoded by an im

268 We confirmed that AT7159 (cyclin-dependent kinase inhibitor), AT9283, (Janus kinase 2/3 i

269 ic upregulation of p57Kip2, a Cip/Kip cyclin-dependent kinase inhibitor, and we identified this induc

270 cally, encapsulation of dinaciclib, a cyclin-dependent kinase inhibitor, into PD-L1-targeted LNPs led

271 cence by repressing the expression of cyclin-dependent kinase inhibitor, p21(Waf1/Cip1).

272 dy, we show that dinaciclib, a potent cyclin dependent kinase inhibitor, significantly increases the

273 of the Skp2-degradation target p27, a cyclin-dependent kinase inhibitor, which was confirmed as the m

274 fforts have led to the development of Cyclin-Dependent Kinase inhibitors (CDKi's) as small molecule d

275 cell cycle, decreasing expression of cyclin-dependent kinase inhibitors and upregulating pro-apoptot

276 isms, including YAP/TAZ signaling and cyclin-dependent kinase inhibitors, by blocking entry into quie

277 olymorphisms in the region of the calmodulin-dependent kinase isoform D (CaMK1D) gene are associated

278 Calcium/calmodulin-dependent kinase kinase (CaMKK) and AMP-activated protei

279 Here we find calcium/calmodulin-dependent kinase kinase (CaMKK2) to be highly expressed

280 Ca(2+)/calmodulin-dependent kinase kinase beta (CaMKKbeta) emerges as a de

281 inases, Polo kinases, and calcium/calmodulin-dependent kinase kinases.

282 Cyclin-dependent kinase-like 5 (CDKL5) deficiency is a neurodev

283 r caused by mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene.

284 Pathogenic mutations in cyclin-dependent kinase-like 5 (CDKL5) result in CDKL5 deficien

285 Cyclin-dependent kinase-like 5 disorder is a severe neurodevelo

286 deficits in mouse and human models of cyclin-dependent kinase-like 5 disorder', by Gao etal.

287 Using the glycolytic ADP-dependent kinases of archaea, including the orders Therm

288 The PI3K/phosphoinositide-dependent kinase (PDK) 1 pathway represents the canonica

289 ivated by phosphorylation - and their Ca(2+)-dependent kinase (PhK), are elevated in microsomal extra

290 The second pathway involves cyclin-dependent kinase phosphorylation of Cdc20, which is know

291 and inhibit the double-stranded RNA (dsRNA)-dependent kinase PKR.

292 and inhibit the double-stranded RNA (dsRNA)-dependent kinase PKR.

293 Cyclin-dependent kinases play multiple roles in RNA polymerase

294 issense variants in CDK19, encoding a cyclin-dependent kinase protein family member that predominantl

295 s process through expression of the NFkappaB-dependent kinase proviral integration site for Moloney m

296 nd that phosphorylation by regulatory cyclin-dependent kinases reduces this incorporation.

297 (nuclear ubiquitous casein kinase and cyclin-dependent kinase substrate 1) is a chromatin-associated,

298 elected for cell fitness, enriched in Cyclin-dependent kinase substrates, and evolutionarily conserve

299 hat Magnaporthe oryzae CKS1 encodes a cyclin-dependent kinase subunit, which plays a significant role

300 ADP-dependent kinases were first described in archaea, altho